Cellectis EV / EBITDA

Mi az Cellectis EV / EBITDA?

A EV / EBITDA az Cellectis - N/A

Mi a EV / EBITDA meghatározása?



Az EV / EBITDA a vállalati érték a kamat, az adózás, az értékcsökkenés és az amortizáció előtti eredményekkel elosztva. Ez azt jelenti, hogy mennyire drága egy állomány, és gyakrabban érvényesül a vállalatok közötti összehasonlításnál, mint az ár / nyereség arány. Megméri az árat (vállalati érték formájában), amelyet a befektető fizet a vállalat pénzforgalmának javára (EBITDA formájában).

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

Mit csinál Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.